I have been hearing a lot about a new, experimental bone strengthening drug, Prolia, lately. The Myeloma Beacon ran an article about it this week. Did you see it?
A well respected myeloma expert who I have interviewed in the past, Dr. Ravi Vij, spoke with the Beacon about Prolia, which is manufactured by Amgen. His input was mixed. He liked some of the data he saw, but he closed by saying: “The data set comparing the efficacy of Zometa with Prolia is very limited. An adequately powered study needs to be done in order to answer this question.”
Apparently, one of the strengths of Prolia is its “half life,” or how long it stays in your system. Zometa and the other most commonly used bisphosphonate for multiple myeloma patients, Aredia, continues to hang around and stays in your system for years. Prolia is said to only remain active in your body for a few months.
There could be advantages and disadvantages to this–and honestly, I don’t know enough about Prolia yet to comment here. I’m sure we will be hearing much more about it as time goes on.
I do know the more options we have as myeloma patients the better! Multiple myeloma is an enemy to our bones. Anything being developed to help fight this is a positive step. Maybe competition between drug companies will even help keep drug prices down. I’m also anxious to hear more about several drugs under development which are designed to help re-grow bone. Now that will be something to shout about!
Feel good and keep smiling! Pat